Compare Harley-Davidson Inc (HOG) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Pfizer Inc — how do they compare? Harley-Davidson Inc trades at $26.9 (market cap $2.78B), while Pfizer Inc trades at $28.27 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 57× Harley-Davidson Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 92 Days and Pfizer Inc for 158 Days on average.
| HOG | PFE | |
|---|---|---|
Market Cap | $2.78B | $158.56B |
Volume | 2,966,389 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $29.02 |
52-Week Low | $17.19 | $23.67 |
Typical Hold Time | 92 Days | 158 Days |
Enterprise Value | $3.20B | $210.06B |
Dividend Yield | 2.8% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.90, down 0.19% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings beat ($0.75 vs $0.645 expected) but missed Q1 expectations. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, though valuation ratios remain attractive with P/E of 14.86 and P/S of 0.72. Recent news highlights tariff exposure and a data breach investigation.
The stock offers value with reasonable multiples but faces revenue headwinds and operational challenges. Analyst consensus is cautious with 61% hold ratings and $28.50 price target suggesting limited upside. Key risks include declining motorcycle demand, tariff sensitivity, and competitive pressures in the evolving auto industry.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
